Care Needs in Lung Cancer Patients Receiving Immunotherapy

NCT06433206 | Recruiting

• 1 other identifier: 201911078RIND
• Study Type: observational
• Target: 180
• Locations: 1 country
• Sites: 1

Brief Summary

Lung cancer ranks as the leading cause of cancer-related deaths globally and is among the most common malignancies. In recent years, the advancements in immune checkpoint inhibitors have marked a significant breakthrough in the immunotherapy of lung cancer. However, immunotherapy is a relatively new treatment modality, and ongoing clinical trials continue to explore its efficacy. Due to a lack of knowledge about immunotherapy-related care, patients often experience uncertainty and anxiety regarding its effectiveness, resulting in associated care needs. A total of 160 lung cancer patients were included in the study. The research findings revealed statistically significant correlations (p \< 0.05) between the severity of disease, symptomatology, overall health status, functional capacity, cognitive function, disease progression, mood, and general supportive care needs, as well as specific needs of lung cancer patients. Regarding factors influencing care needs, it was found that general supportive care needs were significantly influenced by marital status, average personal monthly income, and disease progression. Additionally, age, surgical history, functional capacity, and cognitive function significantly influenced specific care needs. Based on these statistical findings, it is crucial for nursing staff to closely monitor changes in patients' symptoms and mood and provide timely care and support. Furthermore, future interventions should focus on addressing the heightened needs of lung cancer patients, thereby reducing their dissatisfaction along the cancer treatment journey.

Conditions

Lung Cancer, Immunotherapy, Quality of Life, Symptom Severity, Care Needs

Outcome Measures

Primary Outcomes (1)

• Care Needs in Lung Cancer Patients Receiving Immunotherapy

  1year

Secondary Outcomes (2)

• Quality of Life in Lung Cancer Patients Receiving Immunotherapy

  1year

• Symptom Severity in Lung Cancer Patients Receiving Immunotherapy

  1year

Interventions

no intervention OTHER

no intervention

Eligibility Criteria

• Age: 20 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

Using consecutive sampling, lung cancer patients who have received or are currently undergoing immunotherapy will be selected from a medical center and a specialized cancer hospital in northern Taiwan.

You may qualify if:

• Individuals diagnosed with malignant lung tumors based on imaging or post-surgical histopathological examination results by specialized physicians.
• Individuals who have received immunotherapy in the past or are currently undergoing immunotherapy.
• Research participants who are conscious, aged 20 years or older, able to communicate in Mandarin or Taiwanese, capable of completing the questionnaire, willing to participate in the study, and have signed the research consent form.

You may not qualify if:

• Individuals with significant cognitive impairments who are unable to complete the questionnaire.
• Individuals who are unable to communicate in Mandarin or Taiwanese.

Sponsors & Collaborators

• National Taiwan University Hospital: lead

Study Sites (1)

National Taiwan University Cancer Center

Taipei, Taiwan, 106, Taiwan

RECRUITING

MeSH Terms

Conditions

Lung Neoplasms

Condition Hierarchy (Ancestors)

Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms by Site; Neoplasms; Lung Diseases; Respiratory Tract Diseases

Study Officials

• Meng Ping Hsiao, master

  NTUCC

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Meng Ping Hsiao, master

CONTACT

+886 919865349; A00708@ntucc.gov.tw

Study Design

• Study Type: observational
• Observational Model: CASE ONLY
• Time Perspective: CROSS SECTIONAL
• Target Duration: 1 Day
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 22, 2024
• First Posted: May 29, 2024
• Study Start: April 21, 2021
• Primary Completion (Estimated): December 31, 2027
• Study Completion (Estimated): December 31, 2027
• Last Updated: July 31, 2026

Record last verified: 2026-07

Locations

TW (1)